Apo2L/TRAIL: Interim Phase Ib data

Interim Phase Ib data from 18 evaluable patients showed that Apo2L/TRAIL plus Avastin bevacizumab and chemotherapy produced an overall response rate of 56%. One patient had a complete response and 9 ...